Please login to the form below
Afinitor
This page shows the latest Afinitor news and features for those working in and with pharma, biotech and healthcare.
Novartis buys gene therapy firm AveXis for $8.7bn
some big sellers like cancer drug Afinitor and Gilenya for multiple sclerosis in 2019, according to a report on aktiencheck.de.
Latest news
-
AAA board presses go on $3.9bn Novartis takeover
Novartis has no heritage in this type of medicine but already markets two drugs for NET – Sandostatin (octreotide) and Afinitor/Votubia (everolimus) – so the acquisition makes sense from a franchise perspective, ... Latterly Sandostatin has played
-
NICE gives green light to Ipsen's Cabometyx
Earlier this year NICE performed a similar U-turn on Novartis’kidney cancer drug Afinitor, following an offer of discount earlier and the provision of new evidence.
-
NICE U-turn on Novartis' Afinitor for kidney cancer
NICE U-turn on Novartis' Afinitor for kidney cancer. Set to back treatment's routine NHS use following offer of discount and new data. ... The UK's National Institute for Health and Care Excellence (NICE) has reversed its previous ruling on Afinitor and
-
NICE backs Novartis' Afinitor and Pfizer's Xalkori
NICE backs Novartis' Afinitor and Pfizer's Xalkori. Provisionally approves breast and lung cancer drugs after greater discounts offered. ... NICE has provisionally recommended Novartis' Afinitor and Pfizer's Xalkori for routine use on the NHS in breast
-
NICE U-turn on Opdivo for kidney cancer
In a phase III clinical study, patients treated with Opdivo lived for an average of 5.4 months longer than the group who received Novartis' Afinitor (everolimus), the standard therapy, and
More from news
Approximately 13 fully matching, plus 64 partially matching documents found.
Latest Intelligence
-
Back to the future
The successes of Gilenya, Afinitor/Votubia, Galvus, Tasigna and Jakavi - as well as its generics arm, Sandoz - mean that Novartis is now less than $500m behind Pfizer in second place.
-
Pharma deals during April 2014
Novartis' pipeline includes more than 25 new molecular entities targeting key oncogenic pathways including: Gleevec and its follow-up Tasigna (blood-cancer); Afinitor (kidney cancer and recently approved for breast cancer);
-
Interview: Joseph Jimenez, Novartis
In 2010, we had 13 key product approvals and 16 major filings in pharma, including Gilenya, Lucentis and Afinitor," he points out. ... populations. "In Q2 alone, we had four major approvals and two major filings, including Afinitor, Arcapta Neohaler,
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest appointments
-
Former Novartis exec joins Genmab
cancer drug Afinitor.
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest from PMHub
-
Oncology drugs under AMNOG
patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Sudler London - Senior Medical Writer
-
Competitive
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
- Science Writer, Healthcare Advertising Agency
-
£40, 000 - 45, 000 DOE benefits,
-
Systematic Review Lead- London
-
Negotiable
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
-
Senior Medical Writer
-
Salary is DOE
- Account Manager, Healthcare Advertising
-
£30 - 38, 000 (or -)
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Associate Scientific Director
-
Salary TBC
- Senior Writer, Healthcare Advertising, London
-
Excellent package
-
Account Manager
-
Negotiable
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
Subscribe to our email news alerts
- IPA’s new training course, Silver Buck launched and ARK moves office
- NHS wins legal fight with pharma over off-label Avastin
- Gilead and ViiV among winners at PM Society Digital Awards
- The critical role of science in healthcare communications
- UK pharma to work with innovation network on NHS uptake
- Bayer roll-out of haemophilia drug Jivi gathers pace
PMHub
Weber Shandwick
At Weber Shandwick, engagement has always been the cornerstone of health communications.We make health matter. Health is a basic human...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
